Humana Inc. (HUM) Position Raised by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC increased its stake in Humana Inc. (NYSE:HUM) by 39.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,358,617 shares of the insurance provider’s stock after acquiring an additional 386,162 shares during the quarter. TIAA CREF Investment Management LLC owned approximately 0.94% of Humana worth $326,910,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Independent Portfolio Consultants Inc. increased its holdings in Humana by 22.1% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after acquiring an additional 94 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Humana by 139.5% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after acquiring an additional 325 shares in the last quarter. Fiduciary Trust Co. purchased a new stake in Humana in the 2nd quarter worth $135,000. Guardian Life Insurance Co. of America increased its holdings in Humana by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after acquiring an additional 4 shares in the last quarter. Finally, Point72 Asia Hong Kong Ltd purchased a new stake in Humana in the 1st quarter worth $128,000. 95.14% of the stock is owned by institutional investors.
Humana Inc. (NYSE HUM) traded down 0.573% on Tuesday, reaching $255.735. 239,146 shares of the company’s stock were exchanged. Humana Inc. has a 1-year low of $163.50 and a 1-year high of $259.47. The company has a market capitalization of $36.96 billion, a PE ratio of 21.038 and a beta of 0.87. The company has a 50 day moving average price of $247.99 and a 200-day moving average price of $230.38.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the business posted $2.30 EPS. On average, equities research analysts anticipate that Humana Inc. will post $11.55 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is presently 13.06%.
In other Humana news, VP M Todoroff Christopher sold 22,935 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $252.52, for a total value of $5,791,546.20. Following the sale, the vice president now directly owns 24,001 shares of the company’s stock, valued at approximately $6,060,732.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the completion of the sale, the insider now directly owns 18,042 shares in the company, valued at $4,672,878. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,566 shares of company stock valued at $15,326,746. 0.80% of the stock is currently owned by company insiders.
Several brokerages recently commented on HUM. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $262.00 price target for the company in a report on Wednesday, June 7th. Leerink Swann boosted their price target on shares of Humana from $250.00 to $265.00 and gave the stock an “outperform” rating in a report on Tuesday, May 30th. BidaskClub lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, June 13th. UBS AG reissued a “neutral” rating and issued a $237.00 price target (up previously from $205.00) on shares of Humana in a report on Wednesday, June 28th. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $214.00 price target on shares of Humana in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $244.35.
COPYRIGHT VIOLATION WARNING: “Humana Inc. (HUM) Position Raised by TIAA CREF Investment Management LLC” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/12/humana-inc-hum-position-raised-by-tiaa-cref-investment-management-llc.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.